Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2025 | $162.00 | Neutral | Rothschild & Co Redburn |
| 3/8/2022 | $170.00 → $155.00 | Buy | HC Wainwright & Co. |
| 2/22/2022 | $175.00 | Neutral → Buy | Sidoti |
| 1/10/2022 | $160.00 → $170.00 | Buy | HC Wainwright & Co. |
| 11/29/2021 | $175.00 | Buy → Neutral | Sidoti |
| 8/2/2021 | $140.00 → $145.00 | Overweight → Equal-Weight | Stephens & Co. |
| 8/2/2021 | $145.00 → $160.00 | Buy | HC Wainwright & Co. |
MONTVALE, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, April 30, 2026, at 11:00 AM Eastern Time (ET) to review first quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. First quarter results will be published prior to the market opening on Thursday, April 30, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. Institutional investors, analysts and other members of the financial community are invited to join the live call by
MONTVALE, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Balchem Plant Nutrition, a global leader in chelated mineral plant nutrition and the maker of Metalosate® micronutrients, today announced the launch of its Metalosate® T.E.A.M.™ plant tissue analysis digital platform. The platform helps advisors optimize nutrient balance to enhance yield potential and crop quality, while reducing unnecessary input cost in specialty crops. Built as a free service for pest control advisors and agronomists, T.E.A.M. translates plant tissue analysis results into targeted nutrition recommendations that growers can act on with confidence. T.E.A.M., which stands for Technical Evaluation of Albion Minerals, is a
MONTVALE, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the
Rothschild & Co Redburn initiated coverage of Balchem with a rating of Neutral and set a new price target of $162.00
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously
Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00
10-K - BALCHEM CORP (0000009326) (Filer)
8-K - BALCHEM CORP (0000009326) (Filer)
8-K - BALCHEM CORP (0000009326) (Filer)
MONTVALE, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, April 30, 2026, at 11:00 AM Eastern Time (ET) to review first quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. First quarter results will be published prior to the market opening on Thursday, April 30, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. Institutional investors, analysts and other members of the financial community are invited to join the live call by
MONTVALE, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal fourth quarter and full year ended December 31, 2025. For the quarter, the Company reported net sales of $263.6 million, net earnings of $39.2 million, adjusted EBITDA(a) of $67.9 million, and free cash flow(a) of $51.2 million. For the full year 2025, the Company reported net sales of $1.037 billion, net earnings of $154.8 million, adjusted EBITDA of $274.9 million, and free cash flow of $173.6 million. Ted Harris, Chairman, President, and CEO of Balchem said, "In the fourth quarter, Balchem's strong growth trajectory continued. We delivered record fo
MONTVALE, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 20, 2026, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year 2025 results will be published prior to the market opening on Friday, February 20, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. Institutional investors, analysts and other members of the financial commu
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
3 - BALCHEM CORP (0000009326) (Issuer)
4 - BALCHEM CORP (0000009326) (Issuer)
4 - BALCHEM CORP (0000009326) (Issuer)